Mark Norton, MD
Internal Medicine · Laurel, MSNPI 1881608495
Payments from drug & device makers
Across 324 payments — averaging $14.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$897
- Merck$439
- Boehringer Ingelheim$359
- AstraZeneca$319
- Astellas Pharma US Inc$268
- Pfizer$249
- plus $2K from 32 others
What the payments were for
- Food & beverage$4,648100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 77 | $897 |
| Merck | 35 | $439 |
| Boehringer Ingelheim | 24 | $359 |
| AstraZeneca | 20 | $319 |
| Astellas Pharma US Inc | 18 | $268 |
| Pfizer | 18 | $249 |
| Amgen | 18 | $245 |
| Abbott | 16 | $223 |
| Johnson & Johnson | 15 | $219 |
| Otsuka America Pharmaceutical, Inc. | 7 | $172 |
| AbbVie(2 entities) | 9 | $151 |
| E.r. Squibb & Sons, L.L.C. | 11 | $142 |
| Novartis | 8 | $124 |
| Sumitomo Pharma America, Inc. | 7 | $116 |
| Inspire Medical Systems, Inc. | 2 | $107 |
| Sanofi-aventis U.S. LLC | 6 | $96 |
| Global Blood Therapeutics, Inc. | 4 | $67 |
| Daiichi Sankyo Inc. | 3 | $55 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $48 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $35 |
| Biogen | 2 | $31 |
| Seqirus USA Inc | 2 | $30 |
| Valeritas, Inc. | 1 | $25 |
| Inari Medical, Inc. | 1 | $22 |
| Dexcom, Inc. | 1 | $20 |
| Aimmune Therapeutics, Inc. | 1 | $19 |
| Exact Sciences | 1 | $19 |
| Gilead | 1 | $17 |
| Medtronic | 1 | $15 |
| Concordia Pharmaceuticals Inc. | 1 | $15 |
| Shield Therapeutics Inc | 1 | $14 |
| Insulet Corporation | 1 | $14 |
| Redhill Biopharma Inc. | 1 | $14 |
| Tandem Diabetes Care, Inc. | 1 | $13 |
| Nabriva Therapeutics, PLC | 1 | $13 |
| Amarin Pharma, Inc. | 1 | $13 |
| GSK | 1 | $13 |
| Lilly USA, LLC | 1 | $12 |
How this compares
$4,648 in reported general payments places this provider in the 85th percentile of 846 internal medicine providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 105 | $107,211 |
| EliquisApixaban | 253 | $87,771 |
| JardianceEmpagliflozin | 127 | $82,752 |
| NuplazidPimavanserin Tartrate | 26 | $62,573 |
| XifaxanRifaximin | 36 | $54,445 |
| FarxigaDapagliflozin Propanediol | 115 | $53,788 |
| LinzessLinaclotide | 116 | $53,105 |
| JanuviaSitagliptin Phosphate | 55 | $34,544 |
| MyrbetriqMirabegron | 113 | $33,625 |
| MounjaroTirzepatide | 25 | $28,347 |
| RexultiBrexpiprazole | 32 | $25,929 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 39 | $25,440 |
| SantylCollagenase Clostridium Hist. | 66 | $23,060 |
| Tresiba Flextouch U-200Insulin Degludec | 23 | $20,210 |
| NuedextaDextromethorphan Hbr/Quinidine | 22 | $16,774 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Novolog, Fiasp | $897 | $118,267197 claims |
| Boehringer IngelheimJardiance, Combivent Respimat, Tradjenta | $359 | $101,853162 claims |
| PfizerEliquis, Premarin | $249 | $92,818264 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $35 | $54,44536 claims |
| AstraZenecaFarxiga | $319 | $53,788115 claims |
| AbbVieLinzess | $151 | $53,105116 claims |
| Lilly USA, LLCMounjaro, Trulicity | $12 | $41,58338 claims |
| MerckJanuvia | $439 | $34,54455 claims |
| Astellas Pharma US IncMyrbetriq | $268 | $33,625113 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $13 | $30,94752 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $172 | $25,92932 claims |
| NovartisEntresto | $124 | $16,25426 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 846 internal medicine providers in Mississippi.
Other internal medicine in Laurel
- James HallBrookhaven$4.8M
- Bob HutchinsJackson$4.6M
- Sidney GortonBelzoni$571K
- David PendleyGulfport$336K
- Sarah KerutJackson$319K
- Gabriel HernandezJackson$196K
- Kelly WilkinsonJackson$183K
- Magdy Gorgi-MikhailBiloxi$157K
- Christina BarlowJackson$129K
- Arnold JacksonHattiesburg$121K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.